A 42-year-old woman with chronic rhinosinusitis and recurrent nasal polyps has failed 3 months of intranasal mometasone therapy. Polyps remain large and symptomatic, causing significant nasal obstruction. Endoscopic sinus surgery is planned. Which agent is most appropriate as adjunctive pharmacotherapy to reduce polyp recurrence post-operatively?

Explanation

## Post-operative Management of Recurrent Nasal Polyps **Key Point:** Intranasal corticosteroids remain the cornerstone of post-operative medical therapy to prevent polyp recurrence, even after surgical intervention. Switching to a different potent intranasal steroid (e.g., fluticasone propionate) or continuing the same agent at optimized dosing is standard practice. ### Rationale for Continued Intranasal Corticosteroid 1. **Prevention of Recurrence** - Reduces recurrence rate from ~30% to ~10–15% at 1 year - Must be continued indefinitely or recurrence is likely - Addresses residual inflammatory substrate post-operatively 2. **Fluticasone Propionate Advantages** - Potent intranasal steroid with high topical bioavailability - Can be used as alternative if mometasone tolerance or inadequate response - Twice-daily dosing may improve compliance vs. once-daily agents **High-Yield:** Post-operative intranasal corticosteroid is MANDATORY to reduce recurrence. Omission significantly increases polyp recurrence risk. ### Comparison of Post-operative Adjunctive Agents | Agent | Role | Evidence | Recommendation | |-------|------|----------|----------------| | Intranasal corticosteroid (fluticasone, mometasone) | First-line | Strong | Mandatory post-op | | Montelukast | Adjunctive (aspirin-exacerbated respiratory disease) | Weak–moderate | Consider if AERD | | Omalizumab | Severe eosinophilic disease | Emerging | Experimental; not routine | | Macrolide antibiotics (clarithromycin) | Adjunctive anti-inflammatory | Weak | Not first-line | **Clinical Pearl:** Patients with aspirin-exacerbated respiratory disease (AERD) or eosinophilic polyp disease may benefit from montelukast or biologic therapy (dupilumab, omalizumab) *in addition to* intranasal corticosteroids, but corticosteroids remain the foundation. ### Post-operative Algorithm ```mermaid flowchart TD A[Endoscopic Sinus Surgery for Polyps]:::action --> B[Start/Continue Intranasal Corticosteroid]:::action B --> C{AERD or Eosinophilic Disease?}:::decision C -->|No| D[Fluticasone or Mometasone alone]:::action C -->|Yes| E[Add Montelukast ± Biologic]:::action D --> F[Long-term surveillance endoscopy]:::action E --> F ``` **Warning:** Stopping intranasal corticosteroids post-operatively significantly increases recurrence risk. Patients must understand this is long-term therapy.